4.1.35 Mandatory Disclosures
Consistent with 2 CFR Part 200.113, NIH applicants and recipients must disclose, in a timely manner, in writing to the NIH awarding IC and the HHS Office of Inspector General (OIG) all information related to violations of federal criminal law involving fraud, bribery, or gratuity violations potentially impacting the federal award. Subrecipients must disclose, in a timely manner, in writing to the pass-through entity and the HHS OIG all information related to violations of federal criminal law involving fraud, bribery, or gratuity violations potentially affecting the federal award. Disclosures must be sent in writing to the NIH awarding IC and to the HHS OIG at the following address:
NIH CGMO listed on the NoA for the IC that funded the grant (See Part III: Points of Contact 20 INSTITUTES AND CENTERS)
AND
U.S. Department of Health and Human Services
Office of Inspector General
ATTN: Mandatory Grant Disclosures, Intake Coordinator
330 Independence Avenue, SW, Cohen Building
Room 5527
Washington, DC 20201
URL: https://oig.hhs.gov/fraud/report-fraud/index.asp
(Include "Mandatory Grant Disclosures" in the subject line")
Fax: (202) 205-0604 (Include "Mandatory Grant Disclosures" in subject line) or
Email: MandatoryGranteeDisclosures@oig.hhs.gov
Failure to make required disclosures can result in any of the remedies described in 2 CFR Part 200.339. Remedies for noncompliance and Administrative Requirements - Enforcement Actions, including suspension or debarment (See 2 CFR Part 180 and 376, 31 U.S.C.3321 and Public Policy Requirements and Objectives- Debarment and Suspension), as necessary and appropriate.